VYNE Therapeutics Inc. (NASDAQ:VYNE) Sees Significant Growth in Short Interest

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 82,600 shares, a growth of 65.2% from the October 15th total of 50,000 shares. Approximately 0.7% of the company’s stock are short sold. Based on an average daily trading volume, of 70,400 shares, the days-to-cover ratio is currently 1.2 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Virtu Financial LLC purchased a new position in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 16,199 shares of the company’s stock, valued at approximately $50,000. Virtu Financial LLC owned 0.11% of VYNE Therapeutics as of its most recent filing with the Securities & Exchange Commission. 83.78% of the stock is currently owned by hedge funds and other institutional investors.

VYNE Therapeutics Stock Down 2.4 %

NASDAQ:VYNE opened at $2.84 on Friday. VYNE Therapeutics has a twelve month low of $1.57 and a twelve month high of $4.48. The firm has a market capitalization of $41.89 million, a price-to-earnings ratio of -3.30 and a beta of 1.32. The stock’s 50 day moving average price is $2.26 and its two-hundred day moving average price is $2.19.

VYNE Therapeutics (NASDAQ:VYNE) last issued its earnings results on Wednesday, August 14th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). VYNE Therapeutics had a negative return on equity of 43.73% and a negative net margin of 6,896.55%. The firm had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.11 million. As a group, analysts anticipate that VYNE Therapeutics will post -0.86 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $5.75 price objective on shares of VYNE Therapeutics in a report on Friday, November 8th.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.